Literature DB >> 10674006

Selective oestrogen receptor modulation: molecular pharmacology for the millennium.

A S Levenson1, V C Jordan.   

Abstract

Knowledge of the mechanism of action and pharmacology of tamoxifen and raloxifene, for the prevention of breast cancer and osteoporosis respectively, has opened the door for the discovery of multifunctional medicines. There is now the potential to prevent osteoporosis, coronary heart disease, breast and endometrial cancer in postmenopausal women with elevated risk factors.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10674006     DOI： 10.1016/s0959-8049(99)00183-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  13 in total

Review 1.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

2.  Highly Stereoselective Synthesis of Tetrasubstituted Acyclic All-Carbon Olefins via Enol Tosylation and Suzuki-Miyaura Coupling.

Authors:  Beryl X Li; Diane N Le; Kyle A Mack; Andrew McClory; Ngiap-Kie Lim; Theresa Cravillion; Scott Savage; Chong Han; David B Collum; Haiming Zhang; Francis Gosselin
Journal:  J Am Chem Soc       Date:  2017-07-26       Impact factor: 15.419

3.  Estrogen directly modulates circadian rhythms of PER2 expression in the uterus.

Authors:  Takahiro J Nakamura; Michael T Sellix; Michael Menaker; Gene D Block
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-08-26       Impact factor: 4.310

4.  Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.

Authors:  Hong Liu; Woo-Chan Park; David J Bentrem; Kevin P McKian; Alexander De Los Reyes; Jessica A Loweth; Jennifer MacGregor Schafer; James W Zapf; V Craig Jordan
Journal:  J Biol Chem       Date:  2001-12-20       Impact factor: 5.157

5.  The Dual Estrogen Receptor α Inhibitory Effects of the Tissue-Selective Estrogen Complex for Endometrial and Breast Safety.

Authors:  Sang Jun Han; Khurshida Begum; Charles E Foulds; Ross A Hamilton; Suzanna Bailey; Anna Malovannaya; Doug Chan; Jun Qin; Bert W O'Malley
Journal:  Mol Pharmacol       Date:  2015-10-20       Impact factor: 4.436

6.  Lithium Hexamethyldisilazide-Mediated Enolization of Highly Substituted Aryl Ketones: Structural and Mechanistic Basis of the E/Z Selectivities.

Authors:  Kyle A Mack; Andrew McClory; Haiming Zhang; Francis Gosselin; David B Collum
Journal:  J Am Chem Soc       Date:  2017-08-23       Impact factor: 15.419

7.  A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells.

Authors:  David J Britton; Gary K Scott; Birgit Schilling; Christian Atsriku; Jason M Held; Bradford W Gibson; Christopher C Benz; Michael A Baldwin
Journal:  J Am Soc Mass Spectrom       Date:  2008-03-04       Impact factor: 3.109

8.  Synthesis of highly functionalized tri- and tetrasubstituted alkenes via Pd-catalyzed 1,2-hydrovinylation of terminal 1,3-dienes.

Authors:  Vaneet Saini; Mark O'Dair; Matthew S Sigman
Journal:  J Am Chem Soc       Date:  2015-01-06       Impact factor: 15.419

9.  New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.

Authors:  Margarida Cepa; Georgina Correia-da-Silva; Elisiário J Tavares da Silva; Fernanda M F Roleira; Margarida Borges; Natércia A Teixeira
Journal:  BMC Cell Biol       Date:  2008-07-24       Impact factor: 4.241

10.  Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha.

Authors:  Sandipan Chakraborty; Anait S Levenson; Pradip K Biswas
Journal:  BMC Struct Biol       Date:  2013-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.